1
|
Noriega S, Cardoso-Ortiz J, López-Luna A, Cuevas-Flores MDR, Flores De La Torre JA. The Diverse Biological Activity of Recently Synthesized Nitro Compounds. Pharmaceuticals (Basel) 2022; 15:717. [PMID: 35745635 PMCID: PMC9230682 DOI: 10.3390/ph15060717] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2022] [Revised: 05/30/2022] [Accepted: 06/01/2022] [Indexed: 02/01/2023] Open
Abstract
The search for new and efficient pharmaceuticals is a constant struggle for medicinal chemists. New substances are needed in order to treat different pathologies affecting the health of humans and animals, and these new compounds should be safe, effective and have the fewest side effects possible. Some functional groups are known for having biological activity; in this matter, the nitro group (NO2) is an efficient scaffold when synthesizing new bioactive molecules. Nitro compounds display a wide spectrum of activities that include antineoplastic, antibiotic, antihypertensive, antiparasitic, tranquilizers and even herbicides, among many others. Most nitro molecules exhibit antimicrobial activity, and several of the compounds mentioned in this review may be further studied as lead compounds for the treatment of H. pylori, P. aeruginosa, M. tuberculosis and S. mutans infections, among others. The NO2 moiety triggers redox reactions within cells causing toxicity and the posterior death of microorganisms, not only bacteria but also multicellular organisms such as parasites. The same effect may be present in humans as well, so the nitro groups can be considered both a pharmacophore and a toxicophore at the same time. The role of the nitro group itself also has a deep effect on the polarity and electronic properties of the resulting molecules, and hence favors interactions with some amino acids in proteins. For these reasons, it is fundamental to analyze the recently synthesized nitro molecules that show any potential activity in order to develop new pharmacological treatments that enhance human health.
Collapse
Affiliation(s)
| | - Jaime Cardoso-Ortiz
- Unidad Académica de Ciencias Químicas, Universidad Autónoma de Zacatecas, Zacatecas 98160, Mexico; (S.N.); (A.L.-L.); (M.D.R.C.-F.); (J.A.F.D.L.T.)
| | | | | | | |
Collapse
|
2
|
In Silico Analysis and Experimental Evaluation of Ester Prodrugs of Ketoprofen for Oral Delivery: With a View to Reduce Toxicity. Processes (Basel) 2021. [DOI: 10.3390/pr9122221] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
The present research aimed to synthesize ketoprofen prodrugs and to demonstrate their potentiality for oral treatment to treat chronic inflammation by reducing its hepatotoxicity and gastrointestinal irritation. Methyl 2-(3-benzoyl phenyl) propanoate, ethyl 2-(3-benzoyl phenyl) propanoate and propyl 2-(3-benzoyl phenyl) propanoate was synthesized by esterification and identified by nuclear magnetic resonance (1HNMR) and infrared (IR) spectrometric analysis. In silico SwissADME and ProTox-II analysis stated methyl derivative as ideal candidate for oral absorption, having a >30-fold LD50 value compared to ketoprofen with no hepatotoxicity. Moreover, in vivo hepatotoxicity study demonstrates that these ester prodrugs have significantly lower effects on liver toxicity compared to pure ketoprofen. Furthermore, ex vivo intestinal permeation enhancement ratio was statistically significant (* p < 0.05) compared to ketoprofen. Likewise, the prodrugs were found to exhibit not only remarkable in vitro anti-proteolytic and lysosomal membrane stabilization potentials, but also significant efficiency to alleviate pain induced by inflammation, as well as central and peripheral stimulus in mice model in vivo. These outcomes recommend that ketoprofen ester prodrugs, especially methyl derivative, can be a cost-effective candidate for prolonged treatment of chronic inflammatory diseases.
Collapse
|
3
|
Han Mİ, Atalay P, Tunç CÜ, Ünal G, Dayan S, Aydın Ö, Küçükgüzel ŞG. Design and synthesis of novel (S)-Naproxen hydrazide-hydrazones as potent VEGFR-2 inhibitors and their evaluation in vitro/in vivo breast cancer models. Bioorg Med Chem 2021; 37:116097. [PMID: 33743356 DOI: 10.1016/j.bmc.2021.116097] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2020] [Revised: 02/17/2021] [Accepted: 02/25/2021] [Indexed: 11/21/2022]
Abstract
Naproxen is a common non-steroidal anti-inflammatory drug, which is the most usually used propionic acid derivative for the treatment of many types of diseases. In this study, a series of novel (S)-Naproxen derivatives bearing hydrazide-hydrazone moiety were designed, synthesized, and evaluated for anticancer activity. The structures of these compounds were characterized by spectral (1H-13C NMR, FT-IR, and HR-MS analyses) methods. All synthesized compounds were screened for anticancer activity against two different human breast cancer cell lines (MDA-MB-231 and MCF-7). Among them, (S)-2-(6-methoxynaphthalen-2-yl)-N'-{(E)-[2-(trifluoromethoxy)phenyl]methylidene} propanehydrazide (3a) showed the most potent anticancer activity against both cancer cell lines with a good selectivity (IC50 = 22.42 and 59.81 µM, respectively). Furthermore, the molecular modeling of these compounds was studied on Vascular Endothelial Growth Factor Receptor 2. Inhibition of VEGFR-2 and apoptotic protein Bcl-2 was investigated in MDA-MB-231 cells treated with compound 3a by using Western Blotting. Apoptosis was also detected by staining with DAPI in fluorescence microscopy. Flow Cytometry analyses related to cell cycle phases showed that a dramatic increase in S and M phases was established compared to untreated control cells indicating the cancer cell cycle arrest. The anticancer activity of compound 3a was investigated in the Ehrlich acid tumor model, a well-validated in vivo ectopic breast cancer model, in mice. Our results showed that compound 3a had anticancer activity and decreased the tumor volume in both low (60 mg/kg) and high (120 mg/kg) doses in mice.
Collapse
Affiliation(s)
- M İhsan Han
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Erciyes University, 38039 Kayseri, Turkey.
| | - Pınar Atalay
- Department of Basic Sciences, Faculty of Pharmacy, Erciyes University, 38039 Kayseri, Turkey; Drug Application and Research Center, Erciyes University, 38039 Kayseri, Turkey
| | - Cansu Ümran Tunç
- Drug Application and Research Center, Erciyes University, 38039 Kayseri, Turkey; Department of Biomedical Engineering, Faculty of Engineering, Erciyes University, 38039 Kayseri, Turkey; Genom and Stem Cell Center, Erciyes University, 38039 Kayseri, Turkey
| | - Gökhan Ünal
- Drug Application and Research Center, Erciyes University, 38039 Kayseri, Turkey; Department of Pharmacology, Faculty of Pharmacy, Erciyes University, 38039 Kayseri, Turkey; DEKAM - Experimental Research and Application Center, Erciyes University, 38040 Kayseri, Turkey
| | - Serkan Dayan
- Drug Application and Research Center, Erciyes University, 38039 Kayseri, Turkey
| | - Ömer Aydın
- Department of Biomedical Engineering, Faculty of Engineering, Erciyes University, 38039 Kayseri, Turkey; Genom and Stem Cell Center, Erciyes University, 38039 Kayseri, Turkey; ERKAM - Clinical Engineering Research and Application Center, Erciyes University, 38040 Kayseri, Turkey; ERNAM - Nanotechnology Research and Application Center, Erciyes University, 38040 Kayseri, Turkey
| | - Ş Güniz Küçükgüzel
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, 34854 İstanbul, Turkey
| |
Collapse
|
4
|
Sehajpal S, Prasad DN, Singh RK. Novel ketoprofen–antioxidants mutual codrugs as safer nonsteroidal anti‐inflammatory drugs: Synthesis, kinetic and pharmacological evaluation. Arch Pharm (Weinheim) 2019; 352:e1800339. [DOI: 10.1002/ardp.201800339] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2018] [Revised: 04/02/2019] [Accepted: 04/03/2019] [Indexed: 01/31/2023]
Affiliation(s)
- Shikha Sehajpal
- Department of Pharmaceutical ChemistryGujranwala Guru Nanak Khalsa College of Pharmacy, Civil LinesLudhiana Punjab India
| | - Deo Nandan Prasad
- Department of Pharmaceutical ChemistryShivalik College of PharmacyRupnagar Punjab India
| | - Rajesh K. Singh
- Department of Pharmaceutical ChemistryShivalik College of PharmacyRupnagar Punjab India
| |
Collapse
|
5
|
Shah K, Shrivastava SK, Mishra P. Synthesis, Kinetics and Pharmacological Comparison of a Mutual Prodrug of Mefenamic Acid to Related Physical Mixture. Pharm Chem J 2014. [DOI: 10.1007/s11094-014-1089-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
|
7
|
Singh R, Kumar R, Singh D. Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drugs: Gastrointestinal-Sparing Potential Drugs. J Med Food 2009; 12:208-18. [DOI: 10.1089/jmf.2007.0584] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Affiliation(s)
- Ratan Singh
- Department of P.G. Studies & Research in Chemistry, J.V. Jain (P.G.) College, Saharanpur, Uttar Pradesh, India
| | - Raj Kumar
- Department of P.G. Studies & Research in Chemistry, J.V. Jain (P.G.) College, Saharanpur, Uttar Pradesh, India
| | - D.P. Singh
- Department of P.G. Studies & Research in Chemistry, J.V. Jain (P.G.) College, Saharanpur, Uttar Pradesh, India
| |
Collapse
|
8
|
Liu C, Desai KG. Characteristics of Rofecoxib-Polyethylene Glycol 4000 Solid Dispersions and Tablets Based on Solid Dispersions. Pharm Dev Technol 2008; 10:467-77. [PMID: 16370176 DOI: 10.1080/10837450500299701] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
The aim of this work was to report the properties of rofecoxib-PEG 4000 solid dispersions and tablets prepared using rofecoxib solid dispersions. Rofecoxib is a poorly water soluble nonsteroidal anti-inflammatory drug with a poor dissolution profile. This work investigated the possibility of developing rofecoxib tablets, allowing fast, reproducible, and complete rofecoxib dissolution, by using rofecoxib solid dispersion in polyethylene glycol (PEG) 4000. Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), X-ray diffraction (XRD) and scanning electron microscopy (SEM) were used to characterize the solid state of solid dispersions. The effect of PEG 4000 concentration on the dissolution rate of rofecoxib from its solid dispersions was investigated. The dissolution rate of rofecoxib from its solid dispersions increased with an increasing amount of PEG 4000. The extent of dissolution rate enhancement was estimated by calculating the mean dissolution time (MDT) values. The MDT of rofecoxib decreased significantly after preparing its solid dispersions with PEG 4000. The FTIR spectroscopic studies showed the stability of rofecoxib and absence of well-defined rofecoxib-PEG 4000 interaction. The DSC and XRD studies indicated the amorphous state of rofecoxib in solid dispersions of rofecoxib with PEG 4000. SEM pictures showed the formation of effective solid dispersions of rofecoxib with PEG 4000 since well-defined change in the surface nature of rofecoxib and solid dispersions were observed. Solid dispersions formulation with highest drug dissolution rate (rofecoxib: PEG 4000 1:10 ratio) was used for the preparation of solid dispersion-based rofecoxib tablets by the direct compression method. Solid dispersion-based rofecoxib tablets obtained by direct compression, with a hardness of 8.1 Kp exhibited rapid drug dissolution and produced quick anti-inflammatory activity when compared to conventional tablets containing pure rofecoxib at the same drug dosage. This indicated that the improved dissolution rate and quick anti-inflammatory activity of rofecoxib can be obtained from its solid dispersion-based oral tablets.
Collapse
Affiliation(s)
- Chengsheng Liu
- Life Science College, Ocean University of China, Qingdao, China
| | | |
Collapse
|
9
|
Scatena R, Bottoni P, Martorana GE, Giardina B. Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential. Expert Opin Investig Drugs 2006; 14:835-46. [PMID: 16022573 DOI: 10.1517/13543784.14.7.835] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
The discovery of the multiple physiological and pathophysiological processes in which nitric oxide (NO) is involved has promoted a great number of pharmacological researches to develop new drugs that are capable of influencing NO production directly and/or indirectly for therapeutic purposes (i.e, NO-releasing drugs, NO-inhibiting drugs, and phosphodiesterase V inhibitors). In particular, the so-called NO donor drugs could actually have an important therapeutic effect in the treatment of many diseases such as arteriopathies (atherosclerosis and its sequelae, arterial hypertension and some forms of male sexual impotence), various acute and chronic inflammatory conditions (colitis, rheumatoid arthritis and tissue remodelling), and several degenerative diseases (Alzheimer's disease and cancer). The old organic nitrates show some well-known pitfalls including the induction of tolerance and acute side effects related to abrupt vasodilation such as cephalea and hypotension, which limit their therapeutic indications. A low therapeutic index (i.e., peroxynitrite toxicity) has always characterised the sydnonimines class. A series of interesting new classes of NO donors are under intense pharmacological investigation and scrutiny (S-nitrosothiols, diazeniumdiolates and NO hybrid drugs), each characterised by a particular pharmacokinetic and pharmacodynamic profile. The most important obstacle in the field of NO donor drugs is represented by the difficulty in targeting NO release, and thereby its effects, to a particular tissue.
Collapse
Affiliation(s)
- Roberto Scatena
- Istituto di Biochimica e Biochimica Clinica, Universita' Cattolica, Largo A. Gemelli 8, 00168 Rome, Italy.
| | | | | | | |
Collapse
|
10
|
Abuo-Rahma GEDAA, Horstmann A, Radwan MF, El-Emam A, Glusa E, Lehmann J. NO-donors, part 9 : diazeniumdiolates inhibit human platelet aggregation and induce a transient vasodilatation of porcine pulmonary arteries in accordance with the NO-releasing rates. Eur J Med Chem 2005; 40:281-7. [PMID: 15725497 DOI: 10.1016/j.ejmech.2004.11.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2004] [Revised: 11/09/2004] [Accepted: 11/09/2004] [Indexed: 11/21/2022]
Abstract
Diazeniumdiolates (NONOates), among them a ciprofloxacin-diazeniumdiolate hybrid compound, were synthesized and the pH-, temperature- and structure-dependent liberation of nitric oxide (NO) was monitored by laser magnetic resonance spectroscopy (LMRS). The compounds induced a transient and reversible relaxation (EC(50) 8.3-150 nM) of pulmonary arteries independently from intact endothelium by stimulation of guanylyl cyclase (sGC). Increase in vascular cGMP was observed and blocking sGC with ODQ, an inhibitor of the NO-sensitive guanylyl cyclase, induced a rightward shift of the concentration-response curves. Repeated exposure did not show homologous desensitization. ADP-induced platelet aggregation (IC(50) = 0.15-3 microM, IC(50) for SNP: 2 microM) and collagen-induced aggregation were potently inhibited. Preincubation with ODQ also diminished these inhibitory effects.
Collapse
|
11
|
Decker M, König A, Glusa E, Lehmann J. Synthesis and vasorelaxant properties of hybrid molecules out of NO-donors and the β-receptor blocking drug propranolol. Bioorg Med Chem Lett 2004; 14:4995-7. [PMID: 15341967 DOI: 10.1016/j.bmcl.2004.07.014] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2004] [Revised: 07/05/2004] [Accepted: 07/06/2004] [Indexed: 10/26/2022]
Abstract
S-Nitroso-N-acetylpenicillamine (SNAP) and 3-nitrooxypivaloyl acid were combined in the form of the respective amides with propranolol, in order to obtain prodrugs (NO-propranololes) with beta-receptor blocking properties of the latter compound with nitric oxide releasing properties of the former compounds. A respective nitratoester could not be synthesized, because it immediately rearranges to the amide after deprotection of the amino group. In vitro tests on porcine pulmonary arteries showed that both types of hybrid molecules (6, 12) elicited vasorelaxation, but the nitratoamide was less potent by more than one order of magnitude. The vasorelaxant effect of SNAP was more pronounced than that of the SNAP-hybrid (12), on the other hand the nitratoamide 6 was more potent than 3-nitrooxypivaloyl acid.
Collapse
Affiliation(s)
- Michael Decker
- Lehrstuhl für Pharmazeutische/Medizinische Chemie, Institut für Pharmazie, Friedrich-Schiller-Universität Jena, Philosophenweg 14, D-07743 Jena, Germany.
| | | | | | | |
Collapse
|